# US Antiemetics Market

> US Antiemetics Market Research Report: Size, Share, Trend Analysis By Drug Class (Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, Neurokinin-1 Receptor Antagonists), By Route of Administration (Oral, Intravenous, Transdermal, Rectal, Subcutaneous), By Indication (Chemotherapy-Induced Nausea, Postoperative Nausea and Vomiting, Motion Sickness, Pregnancy-Related Nausea, Radiation-Induced Nausea) and By End Users (Hospitals, Clinics, Homecare Settings, Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.22%
- **2024:** $ 8 Billion
- **2025:** $ 8.34 Billion
- **2035:** $ 12.6 Billion
- **Key Players:** Roche (CH), Novartis (CH), GlaxoSmithKline (GB), Bristol-Myers Squibb (US), Merck & Co. (US), AstraZeneca (GB), Teva Pharmaceutical Industries (IL), Sanofi (FR), Eli Lilly and Company (US)

**Report ID:** MRFR/HC/18034-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-antiemetics-market-19581

---

## Market Summary

## **US Antiemetics Market Overview**

### **Market Size and Growth**

As per MRFR analysis, the US Antiemetics Market Size was estimated at 7.56 (USD Billion) in 2023. The US Antiemetics Market Industry is expected to grow from 8.5 (USD Billion) in 2024 to 14 (USD Billion) by 2035. The US Antiemetics Market CAGR (growth rate) is expected to be around 4.641% during the forecast period (2025 - 2035).

### **Key Market Trends**

The US antiemetics market is currently experiencing several key trends driven by a growing demand for effective nausea and vomiting treatment options. The increasing prevalence of conditions that cause emesis, such as chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea, is a significant market driver. Efforts by healthcare providers to improve patient management, especially in oncology and surgery, have led to heightened usage of antiemetics.

Additionally, there is a shift towards personalized medicine, where treatments are tailored to individual patient responses, optimizing therapeutic outcomes. Opportunities exist in the development of novel drug formulations, including those that can target specific receptors or pathways involved in emesis. The growing interest in non-pharmacological solutions, like acupuncture and behavioral therapies, also highlights avenues for complementary approaches alongside existing drug therapies.

Furthermore, the US Food and Drug Administration (FDA) is actively reviewing and approving new antiemetic agents, which encourages innovation while addressing market demand. In recent times, the trend towards over-the-counter antiemetic medications has gained traction, providing consumers with greater access to these treatments. This shift reflects an increase in awareness and willingness among individuals to manage mild to moderate nausea independently.

Additionally, there is a growing focus on education about the side effects of existing medications, prompting patients to seek integrated solutions. The confluence of these factors is shaping the US antiemetics market, aligning it with both clinical needs and patient preferences.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Antiemetics Market Drivers**

### **Rising Incidence of Nausea-Related Conditions**

The US [Antiemetics Market](../../../reports/antiemetics-market-8454) Industry is experiencing significant growth due to an increasing prevalence of nausea-related conditions such as cancer, gastrointestinal disorders, and migraine. According to the National Cancer Institute, it is estimated that there will be around 1.9 million new cancer cases diagnosed in the United States in 2021 alone. Many cancer patients experience nausea due to chemotherapy treatments, which drives the demand for effective antiemetic medications.

Moreover, the American Gastroenterological Association reports that approximately 35 percent of individuals suffering from gastrointestinal disorders also report persistent nausea, further contributing to market demands. Pharmaceutical companies such as Merck and GlaxoSmithKline have recognized these trends, investing heavily in Research and Development to create innovative treatments. 
These companies are focusing on developing new drugs with enhanced efficacy and fewer side effects, which is essential given the growing patient population suffering from these debilitating conditions.The rise in diagnosed cases and the need for effective therapeutics strongly support the growth of the US Antiemetics Market.

### **Advancements in Drug Formulation and Delivery**

Technological advancements in drug formulation and delivery mechanisms are significantly influencing the US Antiemetics Market Industry. New formulations, such as liposomal or extended-release antiemetic medications, enhance patient compliance and allow for optimized dosing regimens. Organizations like the Food and Drug Administration (FDA) have been actively approving innovative delivery systems. The FDA approved a novel sublingual antiemetic drug in recent years, which has shown increased bioavailability and faster onset of action, thus improving treatment outcomes.

This trend towards advanced drug delivery systems is expected to drive the market, as patients are increasingly seeking more efficient and convenient treatment options.

### **Increased Awareness and Diagnosis of Nausea-Related Disorders**

Awareness campaigns and enhanced diagnostic capabilities are also propelling the US Antiemetics Market Industry forward. Organizations like the American Society of Clinical Oncology have raised awareness about nausea management in cancer care, prompting both healthcare professionals and patients to seek better diagnosis and treatment options. As awareness increases, it leads to better diagnosis of nausea-related conditions, which in turn increases the number of prescriptions for antiemetics.

Statistically, there has been a reported 20 percent increase in antiemetic prescriptions over the past five years as healthcare providers better identify the need for these medications in treatment plans, supporting the overall growth of the market.

### **Growing Geriatric Population Prone to Nausea**

The demographic shift towards an aging population in the United States is a significant driver for the US Antiemetics Market Industry. According to the Administration for Community Living, roughly 54 million Americans aged 65 and older were reported in 2019, with projections suggesting this number will rise to over 80 million by 2040. Elderly individuals are more susceptible to conditions causing nausea, such as chronic illnesses and comorbidities.

This demographic change creates a higher demand for antiemetic therapies, necessitating a responsive approach from pharmaceutical companies. Major players such as Pfizer and Johnson & Johnson are allocating substantial resources to Research and Development focused on elder-specific antiemetic formulations, catering directly to this growing need.

## **US Antiemetics Market Segment Insights**

### **Antiemetics Market Drug Class Insights**

The US Antiemetics Market showcases a diverse landscape within the Drug Class segment, which plays a vital role in addressing various types of nausea and vomiting. This segment exhibits a segmented structure, comprising Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, and Neurokinin-1 Receptor Antagonists. Each of these classes addresses specific causes and pathways associated with emesis, making them crucial in clinical treatment practices across various settings.

Serotonin 5-HT3 Receptor Antagonists are particularly significant, primarily used in managing chemotherapy-induced nausea and postoperative vomiting, highlighting their importance in oncological therapies and surgical recovery. These drugs act by blocking serotonin receptors in the central nervous system and gastrointestinal tract, providing effective relief for patients undergoing intense treatment regimens. Additionally, Dopamine Antagonists are valued for their broad-spectrum efficacy against different types of nausea, including that experienced in motion sickness and due to gastrointestinal disturbances.

Their mechanism involves inhibiting dopamine receptors in the brain, which helps mitigate symptoms effectively. Antihistamines have long been a staple in the treatment of motion sickness and allergies, reflecting their longstanding presence in the market. Their action primarily centers on blocking histamine receptors, which can provide relief from symptoms associated with travel and allergic reactions. Cannabinoids have emerged as a novel class of agents in recent years, particularly in the context of chronic conditions such as cancer and HIV/AIDS.

By interacting with the endocannabinoid system, they offer alternative solutions for patients who may not find relief from traditional treatments. Neurokinin-1 Receptor Antagonists are gaining traction due to their effectiveness in preventing acute and delayed nausea in patients undergoing chemotherapy. 
Their unique action on the neurokinin-1 receptor within the central nervous system makes them invaluable in comprehensive antiemetic therapy. The combination of these various drug classes indicates a robust and continually evolving market aimed at improving patient outcomes and addressing unmet medical needs in the realm of nausea and vomiting management.

The continuous innovation in drug development, along with rising healthcare expenditures and an aging population in the US, will likely further propel the growth within this critical Drug Class segment of the US Antiemetics Market. As healthcare providers seek effective management strategies for nausea and vomiting, the importance of each drug class will remain a focal point for ongoing research and development efforts in the industry, signifying the dynamic nature of the US Antiemetics Market overall.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Antiemetics Market Route of Administration Insights**

The Route of Administration segment within the US Antiemetics Market plays a crucial role in addressing the varying needs of patients requiring antiemetic therapies. Different administration methods cater to diverse patient populations and clinical situations. Oral administration, being the most common route, ensures ease of use and accessibility for patients, making it a primary choice for managing nausea and vomiting. Intravenous administration is significant for acute situations, allowing for rapid onset of action, especially in hospitalized settings.

Transdermal patches provide a convenient alternative, offering sustained drug release and higher compliance rates among patients who may struggle with oral intake. Rectal administration, while less commonly discussed, presents an important option for patients unable to take medications orally due to nausea or vomiting, particularly in pediatrics. Subcutaneous routes facilitate self-administration and can be effective in settings where intravenous access is challenging. The choice of route significantly impacts treatment effectiveness, patient adherence, and overall therapeutic outcomes, making the Route of Administration a vital component of the US Antiemetics Market landscape.

With ongoing advancements in drug delivery systems and patient-centered approaches, this segment continues to evolve, presenting both challenges and opportunities in the competitive market.

### **Antiemetics Market Indication Insights**

The US Antiemetics Market segmentation under the Indication category addresses various conditions requiring antiemetic treatment, reflecting significant healthcare needs within the population. Chemotherapy-Induced Nausea is a key area, driven by the rising incidence of cancer and subsequent treatments, requiring effective nausea management to enhance patient quality of life. Postoperative Nausea and Vomiting is also a critical segment, often affecting surgical patients, necessitating efficient solutions to improve recovery experiences.

Motion Sickness remains prevalent among travelers, creating demand for effective treatments to alleviate symptoms during transit. Pregnancy-Related Nausea presents a unique challenge, as it is a common condition among expectant mothers, requiring safe and effective remedies to support maternal well-being. Lastly, Radiation-Induced Nausea constitutes an important area of focus due to the ongoing use of radiation therapy in cancer treatment. The diverse landscape of indications indicates a broad necessity for innovative antiemetic therapies tailored to specific patient circumstances, driving advancements in the US Antiemetics Market.

Furthermore, ongoing research and development efforts aim to enhance treatment efficacy, responding to the nuanced needs of affected individuals across these various conditions.

### **Antiemetics Market End User Insights**

The US Antiemetics Market has shown notable segmentation based on end users, primarily encompassing Hospitals, Clinics, Homecare Settings, and Pharmacies, each playing a vital role in the distribution and utilization of antiemetic drugs. Hospitals serve as a central hub, dealing with complex cases requiring acute management of nausea and vomiting, thereby significantly driving demand for effective antiemetics. Clinics, on the other hand, offer treatment options for outpatients, catering to those with less severe ailments and providing essential support for chronic conditions.

Homecare Settings are increasingly recognized for their importance due to the rising trend of personalized care, allowing patients to manage their symptoms in a comfortable environment, which enhances adherence to treatment protocols. Pharmacies remain a critical access point for patients seeking over-the-counter options, supporting widespread availability and education on antiemetic use. Collectively, these end users contribute to a comprehensive network ensuring that patients receive necessary care, reflecting broad market penetration and varying consumer needs across the healthcare continuum.

The growing emphasis on patient-centered care and advancements in therapeutic options will likely further influence the evolution and dynamics of these segments within the US Antiemetics Market.

## **US Antiemetics Market Key Players and Competitive Insights**

The US Antiemetics Market is characterized by a dynamic landscape, driven by an increasing demand for effective treatment options to combat nausea and vomiting associated with various medical conditions, including chemotherapy, surgery, and motion sickness. This market is witnessing substantial growth due to rising healthcare expenditures, more advanced drug formulations, and heightened awareness about the availability of antiemetic therapies. Competitive dynamics are shaped by the constant evolution of product offerings, the emphasis on clinical effectiveness, and the strategic maneuvering of key players within the sector.

Innovation plays a pivotal role, with companies striving to expand their portfolios and improve patient outcomes by developing new drugs and therapies tailored to specific needs. Merck and Co has established a significant presence in the US Antiemetics Market, capitalizing on its robust research and development capabilities to deliver effective solutions. The company boasts a strong pipeline of antiemetic drugs, which are backed by extensive clinical trials demonstrating their efficacy in alleviating nausea and vomiting. Merck's strength lies in its ability to leverage its wide-reaching distribution network and partnerships with healthcare professionals to enhance patient accessibility to its antiemetic medications.

Additionally, its commitment to innovation ensures that the company remains competitive by continuously updating its product offerings and integrating the latest scientific advancements to optimize treatment outcomes. Bristol Myers Squibb has a notable market presence in the US Antiemetics Market, primarily through its focus on providing high-quality therapies aimed at managing nausea and vomiting in patients undergoing cancer treatments. The company is recognized for its key products that are designed to effectively address these symptoms, ensuring patient adherence to cancer regimens.

Bristol Myers Squibb has invested significantly in research and development, which has enhanced its portfolio with innovative solutions tailored for specific patient populations. The company’s strategic mergers and acquisitions have further solidified its competitive stance, allowing for the integration of complementary products and widening its market reach. Bristol Myers Squibb’s dedication to advancing antiemetic care is evident through its collaboration with healthcare providers, which helps to improve treatment processes and patient outcomes across the United States.

### **Key Companies in the US Antiemetics Market Include**

- **[Merck and Co](https://www.msdvetmanual.com/multimedia/table/antiemetic-drugs)**
- Bristol Myers Squibb
- Novartis
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Eli Lilly and Company
- Pfizer
- Amgen
- Roche
- AbbVie
- Sanofi
- Johnson and Johnson
- Mylan
- Teva Pharmaceuticals

## **US Antiemetics Market Industry Developments**

Recent developments in the US Antiemetics Market indicate a growing focus on innovative therapies and expanded accessibility. Companies like Merck and Co., Bristol Myers Squibb, Novartis, AstraZeneca, GlaxoSmithKline, and Gilead Sciences are actively engaging in Research and Development initiatives to enhance their product portfolios. Notably, in April 2023, Eli Lilly and Company launched an advanced antiemetic drug, which has positively impacted patient outcomes and market acceptance.

In terms of mergers and acquisitions, AbbVie’s acquisition of a biotechnology firm in March 2022, aimed at enhancing antiemetic therapies, has drawn attention, reflecting a strategic shift towards consolidating strengths in this domain. Market valuations have continued to rise, with Pfizer and Amgen reporting increased revenues due to the growing demand for innovative antiemetic treatments following the surge in chemotherapy use. 
Furthermore, regulatory changes and increased awareness regarding nausea treatment options have accelerated market growth, encouraging pharmaceutical firms to invest heavily in this segment.These dynamics are expected to shape the US Antiemetics Market landscape significantly in the coming years.

## **US Antiemetics Market Segmentation Insights**

### **Antiemetics Market Drug Class Outlook**

- Serotonin 5-HT3 Receptor Antagonists
- Dopamine Antagonists
- Antihistamines
- Cannabinoids
- Neurokinin-1 Receptor Antagonists

### **Antiemetics Market Route of Administration Outlook**

- Oral
- Intravenous
- Transdermal
- Rectal
- Subcutaneous

### **Antiemetics Market Indication Outlook**

- Chemotherapy-Induced Nausea
- Postoperative Nausea and Vomiting
- Motion Sickness
- Pregnancy-Related Nausea
- Radiation-Induced Nausea

### **Antiemetics Market End User Outlook**

- Hospitals
- Clinics
- Homecare Settings
- Pharmacies

## Market Drivers

### Advancements in Drug Formulations

Innovations in drug formulations are playing a crucial role in shaping the antiemetics market. The development of long-acting formulations and combination therapies is enhancing the efficacy and convenience of antiemetic treatments. For instance, the introduction of transdermal patches and orally disintegrating tablets is providing patients with more options for managing nausea. These advancements are likely to improve patient adherence to treatment regimens, which is essential for effective nausea management. As pharmaceutical companies continue to invest in research and development, the antiemetics market is expected to benefit from a wider array of innovative products that cater to diverse patient preferences and needs.

### Increasing Healthcare Expenditure

The rising healthcare expenditure in the US is a significant driver for the antiemetics market. As healthcare spending continues to grow, there is a corresponding increase in the availability of advanced medical treatments, including antiemetic therapies. In 2025, healthcare expenditure in the US is projected to reach approximately $4 trillion, reflecting a commitment to improving patient care. This financial investment is likely to facilitate the development and accessibility of antiemetic medications, ensuring that patients have access to effective treatments for nausea. Furthermore, increased healthcare spending may lead to greater insurance coverage for antiemetic therapies, further driving market growth as more patients seek and receive treatment.

### Rising Awareness of Nausea Management

There is a notable increase in awareness regarding the importance of nausea management among both healthcare professionals and patients, which is influencing the antiemetics market. Educational initiatives and campaigns aimed at highlighting the impact of nausea on quality of life are gaining traction. This heightened awareness is likely to lead to more patients seeking treatment for nausea-related conditions, thereby driving demand for antiemetic medications. In the US, healthcare providers are increasingly recognizing the need for effective nausea management strategies, which may result in a shift towards prescribing antiemetics more frequently. Consequently, this trend could contribute to the overall growth of the antiemetics market as more individuals are treated for nausea.

### Regulatory Support for Antiemetic Innovations

Regulatory bodies in the US are increasingly supportive of the development and approval of new antiemetic therapies, which serves as a significant driver for the antiemetics market. The FDA has streamlined the approval process for novel antiemetic drugs, particularly those targeting specific patient populations, such as cancer patients. This regulatory environment encourages pharmaceutical companies to invest in research and development, leading to a broader range of treatment options. As a result, the market is likely to witness an influx of innovative antiemetic products, catering to diverse patient needs. The potential for expedited approvals and favorable regulatory pathways may further stimulate market growth, as companies aim to capitalize on emerging opportunities.

### Growing Incidence of Nausea-Related Conditions

The rising prevalence of nausea-related conditions, such as motion sickness, chemotherapy-induced nausea, and postoperative nausea, is a key driver for the antiemetics market. In the US, it is estimated that approximately 30% of patients undergoing chemotherapy experience severe nausea, necessitating effective antiemetic therapies. This growing patient population is likely to increase the demand for antiemetic medications, thereby propelling market growth. Furthermore, the increasing awareness of nausea management among healthcare providers and patients contributes to the expansion of the antiemetics market. As more individuals seek treatment options, pharmaceutical companies are incentivized to innovate and develop new antiemetic drugs, enhancing the overall market landscape.

## Future Outlook

The [Antiemetics Market](https://www.marketresearchfuture.com/reports/antiemetics-market-8454) is projected to grow at a 4.22% CAGR from 2025 to 2035, driven by increasing demand for effective nausea management and advancements in drug formulations.

**New opportunities:**

- Development of personalized antiemetic therapies for specific patient demographics. Expansion of telehealth services for remote antiemetic consultations. Investment in AI-driven drug discovery for novel antiemetic compounds.

By 2035, the antiemetics market is expected to achieve robust growth, reflecting evolving healthcare needs.

## Segment Insights

### By Drug Class: Serotonin 5-HT3 Receptor Antagonists (Largest) vs. Cannabinoids (Fastest-Growing)

The US antiemetics market is significantly influenced by various drug classes, with Serotonin 5-HT3 Receptor Antagonists leading the market. This class has consistently captured the largest market share, reflecting its effectiveness in treating nausea and vomiting associated with chemotherapy and post-operative care. Dopamine Antagonists and Antihistamines also hold substantial shares, but they face stiff competition from emerging therapies. Cannabinoids, while smaller in share, are gaining traction due to increasing legalization and acceptance, particularly among patients seeking alternative treatments.

Growth trends within the drug class segment show a clear shift as Cannabinoids emerge as the fastest-growing option, driven by a rising awareness of their therapeutic benefits. The endorsement by regulatory bodies and a growing patient population are contributing to this trend. Similarly, Serotonin 5-HT3 Receptor Antagonists are expected to maintain their dominance due to ongoing clinical advancements, while Dopamine Antagonists and Neurokinin-1 Receptor Antagonists continue to play critical roles in managing various conditions, adapting to incorporate new evidence and treatment practices.

Serotonin 5-HT3 Receptor Antagonists (Dominant) vs. Cannabinoids (Emerging)

Serotonin 5-HT3 Receptor Antagonists are recognized for their pivotal role in managing acute nausea and vomiting, particularly linked to cancer treatments. They dominate the US antiemetics market due to their long-standing efficacy and safety profile, making them the first-line treatment in various protocols. Meanwhile, Cannabinoids are emerging as a notable alternative, driven by trends favoring natural products and their use in chronic pain and nausea management. As regulatory landscapes evolve, Cannabinoids are positioned to capture a broader patient base, especially among those hesitant to use traditional medications. The dynamic between these two classes illustrates a robust market landscape, adapting to both clinical needs and patient preferences.

### By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the US antiemetics market, the route of administration segment showcases a diverse distribution, with oral medications taking the largest share due to their convenience and patient preference. Intravenous administration follows, but its growth is remarkable as it caters to severe cases where rapid action is essential. Other routes like transdermal, rectal, and subcutaneous are less prominent yet play crucial roles depending on specific patient needs and clinical scenarios.

Growth trends in this segment are largely driven by the rising prevalence of nausea and vomiting related to various medical conditions and treatments, particularly chemotherapy. The increasing development of advanced formulations and delivery systems further propels the intravenous route, making it the fastest-growing segment. Innovations aimed at enhancing patient compliance and efficacy are also contributing to the expanded use of oral and other routes.

Route of Administration: Oral (Dominant) vs. Intravenous (Emerging)

The oral route remains the dominant method of administration in the US antiemetics market due to its ease of use and favorable patient compliance. This method is widely preferred for outpatient settings and routine nausea management. On the other hand, the intravenous route is emerging vigorously, particularly in hospital settings, where rapid onset of action is critical. This route is often utilized for patients undergoing chemotherapy or those experiencing severe nausea. The differences in application highlight the oral route's stability and consistency against the intravenous method's responsiveness and adaptability to urgent medical needs, making both crucial in comprehensive antiemetic therapies.

### By Indication: Chemotherapy-Induced Nausea (Largest) vs. Postoperative Nausea and Vomiting (Fastest-Growing)

In the US antiemetics market, the indication segment is predominantly characterized by Chemotherapy-Induced Nausea, which commands the largest share among the various indications. This segment is significantly driven by the increasing incidence of cancer cases and the consequent rise in chemotherapy treatments. Other notable indications include Postoperative Nausea and Vomiting, which is gaining relevance due to the rising number of surgical procedures performed, indicating a changing competitive landscape in terms of market share distribution.

Growth trends within the indication segment are showcased by the rapid expansion of Postoperative Nausea and Vomiting, which stands out as the fastest-growing category. Factors propelling this growth include advancements in surgical techniques and increased awareness of patient care, contributing to higher utilization of antiemetics in postoperative settings. Additionally, the rise in preventive healthcare measures and improved clinical guidelines regarding nausea management post-surgery are further projected to enhance market dynamics for this indication.

Chemotherapy-Induced Nausea (Dominant) vs. Motion Sickness (Emerging)

Chemotherapy-Induced Nausea remains the dominant segment within the US antiemetics market, primarily due to the well-established protocols for managing nausea associated with cancer therapies. This segment benefits from a wide range of drug options and continual research devoted to improving treatment outcomes. In contrast, Motion Sickness is emerging as a noteworthy segment, gradually gaining traction as awareness around various non-pharmaceutical interventions, such as lifestyle modifications and behavioral techniques, expands. As public interest in holistic and alternative approaches rises, Motion Sickness is projected to witness enhanced growth, driven by consumer demand for effective solutions in travel-related nausea management.

### By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the US antiemetics market, the distribution of the market share among end-user segments reveals that hospitals maintain the largest share, driven by high patient volumes and the critical need for effective antiemetic therapies. Followed by clinics, pharmacies, and homecare settings, the latter shows a noteworthy rise in demand as more patients opt for at-home treatments, reflecting a shift in patient care models.

The growth trends in this segment are influenced by several factors, including an increasing prevalence of conditions inducing nausea, such as chemotherapy for cancer patients. Moreover, the shift towards outpatient care has propelled the use of antiemetics in homecare settings, making this segment the fastest-growing in the market, catering to the rising preference for integrated home health solutions and personalized care options.

Hospitals (Dominant) vs. Clinics (Emerging)

In the US antiemetics market, hospitals play a dominant role due to their comprehensive facilities and the necessity of managing acute conditions effectively. Their established protocols ensure optimal medication utilization, particularly during high-stakes treatments like chemotherapy. Conversely, clinics represent an emerging segment, gradually gaining traction as they provide accessible healthcare solutions for antiemetic treatments, especially for patients in outpatient settings. This trend reflects the broader movement towards decentralized healthcare, where clinics are becoming increasingly integrated into patient care pathways. The convenience and targeted services offered by clinics attract patients seeking alternatives beyond traditional hospital visits.

## Competitive Benchmarking

The antiemetics market exhibits a dynamic competitive landscape characterized by innovation and strategic maneuvering among key players. Companies such as Roche (CH), Merck & Co. (US), and Bristol-Myers Squibb (US) are at the forefront, leveraging their extensive research capabilities and established market presence to drive growth. Roche (CH) focuses on developing novel therapies that address unmet medical needs, while Merck & Co. (US) emphasizes partnerships to enhance its product pipeline. Bristol-Myers Squibb (US) is strategically positioned through its commitment to oncology-related antiemetics, reflecting a targeted operational focus that aligns with current treatment trends. Collectively, these strategies contribute to a competitive environment that is increasingly shaped by innovation and therapeutic advancements.Key business tactics within the antiemetics market include localized manufacturing and supply chain optimization, which are essential for meeting regional demands and ensuring product availability. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is pronounced, as they often set the pace for innovation and pricing strategies, thereby shaping the overall market dynamics.
In October Roche (CH) announced the successful completion of a Phase III clinical trial for its new antiemetic drug, which targets chemotherapy-induced nausea and vomiting. This development is significant as it not only reinforces Roche's commitment to oncology but also positions the company to capture a larger share of the antiemetics market. The successful trial results may lead to expedited regulatory approval, enhancing Roche's competitive edge.
In September Merck & Co. (US) entered into a strategic partnership with a biotechnology firm to co-develop a next-generation antiemetic. This collaboration is indicative of Merck's strategy to bolster its product offerings through innovative partnerships. By leveraging the biotechnology firm's expertise, Merck aims to accelerate the development of more effective treatments, thereby enhancing its market position.
In August Bristol-Myers Squibb (US) expanded its portfolio by acquiring a smaller pharmaceutical company specializing in antiemetic therapies. This acquisition is likely to enhance Bristol-Myers Squibb's capabilities in the antiemetics segment, allowing for a broader range of treatment options. The integration of new technologies and products from the acquired company could provide a competitive advantage in a market that increasingly values comprehensive treatment solutions.
As of November current trends in the antiemetics market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, as companies recognize the need for collaboration to drive innovation and efficiency. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements and supply chain reliability. This transition underscores the importance of innovation as a key driver of market success.

## Recent News & Developments

Recent developments in the US Antiemetics Market indicate a growing focus on innovative therapies and expanded accessibility. Companies like Merck and Co., Bristol Myers Squibb, Novartis, AstraZeneca, GlaxoSmithKline, and Gilead Sciences are actively engaging in Research and Development initiatives to enhance their product portfolios. Notably, in April 2023, Eli Lilly and Company launched an advanced antiemetic drug, which has positively impacted patient outcomes and market acceptance.

In terms of mergers and acquisitions, AbbVie’s acquisition of a biotechnology firm in March 2022, aimed at enhancing antiemetic therapies, has drawn attention, reflecting a strategic shift towards consolidating strengths in this domain. Market valuations have continued to rise, with Pfizer and Amgen reporting increased revenues due to the growing demand for innovative antiemetic treatments following the surge in chemotherapy use. Furthermore, regulatory changes and increased awareness regarding nausea treatment options have accelerated market growth, encouraging pharmaceutical firms to invest heavily in this segment.These dynamics are expected to shape the US Antiemetics Market landscape significantly in the coming years.

## Report Scope

| MARKET SIZE 2024 | 8.0(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 8.34(USD Billion) |
| MARKET SIZE 2035 | 12.6(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.22% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Novartis (CH), GlaxoSmithKline (GB), Bristol-Myers Squibb (US), Merck & Co. (US), AstraZeneca (GB), Teva Pharmaceutical Industries (IL), Sanofi (FR), Eli Lilly and Company (US) |
| Segments Covered | Drug Class, Route of Administration, Indication, End User |
| Key Market Opportunities | Emerging therapies targeting specific nausea causes present growth potential in the antiemetics market. |
| Key Market Dynamics | Rising demand for innovative antiemetics drives competition and regulatory scrutiny in the evolving healthcare landscape. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US antiemetics market in 2024?**
A: The overall market valuation was $8.0 Billion in 2024.

**Q: What is the projected market valuation for the US antiemetics market by 2035?**
A: The projected valuation for 2035 is $12.6 Billion.

**Q: What is the expected CAGR for the US antiemetics market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 4.22%.

**Q: Which drug class segment had the highest valuation in 2024?**
A: The Serotonin 5-HT3 Receptor Antagonists segment had the highest valuation at $2.4 Billion in 2024.

**Q: What is the projected valuation for the Oral route of administration by 2035?**
A: The projected valuation for the Oral route of administration is $3.8 Billion by 2035.

**Q: Which end user segment is expected to grow the most by 2035?**
A: The Pharmacies segment is expected to grow the most, with a projected valuation of $4.3 Billion by 2035.

**Q: What was the valuation of the Cannabinoids segment in 2024?**
A: The Cannabinoids segment was valued at $1.0 Billion in 2024.

**Q: How much is the Postoperative Nausea and Vomiting indication projected to be worth by 2035?**
A: The Postoperative Nausea and Vomiting indication is projected to be worth $2.5 Billion by 2035.

**Q: Which company is one of the key players in the US antiemetics market?**
A: Roche is one of the key players in the US antiemetics market.

**Q: What was the valuation of the Neurokinin-1 Receptor Antagonists segment in 2024?**
A: The Neurokinin-1 Receptor Antagonists segment was valued at $1.8 Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-antiemetics-market-19581*